HOMOLOGY MEDICINES INC (FIXX) Stock Price, Quote, News and Overview
NASDAQ:FIXX - Nasdaq - US4380831077 - Common Stock - Currency: USD
FIXX Quote, Performance and Key Statistics
0.9347
+0.01 (+0.77%)
The current stock price of FIXX is 0.9347 USD. In the past month the price increased by 4.8%. In the past year, price decreased by -9.25%.
FIXX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About FIXX
Company Profile
Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 92 full-time employees. The company went IPO on 2018-03-28. The Company’s clinical programs include HMI-103, an investigational gene editing candidate in clinical development for the treatment of patients with phenylketonuria (PKU); HMI-203, an investigational gene therapy candidate in clinical development for the treatment of patients with mucopolysaccharidosis type II (MPS II), or Hunter syndrome; and HMI-102, an investigational gene therapy candidate in clinical development for the treatment of adult patients with PKU. Its lead GTx-mAb gene therapy candidate, HMI-104, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). Its platform is designed to utilize human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs), to precisely and efficiently deliver single administration genetic medicines in vivo through a nuclease-free gene editing modality and gene therapy platform.
Company Info
HOMOLOGY MEDICINES INC
1 Patriots Park
Bedford MASSACHUSETTS 01730 US
CEO: Arthur O. Tzianabos
Employees: 92
Company Website: https://www.homologymedicines.com/
Phone: 17813017277
HOMOLOGY MEDICINES INC / FIXX FAQ
What is the stock price of HOMOLOGY MEDICINES INC today?
The current stock price of FIXX is 0.9347 USD. The price increased by 0.77% in the last trading session.
What is the ticker symbol for HOMOLOGY MEDICINES INC stock?
The exchange symbol of HOMOLOGY MEDICINES INC is FIXX and it is listed on the Nasdaq exchange.
On which exchange is FIXX stock listed?
FIXX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for HOMOLOGY MEDICINES INC stock?
6 analysts have analysed FIXX and the average price target is 1.53 USD. This implies a price increase of 63.69% is expected in the next year compared to the current price of 0.9347. Check the HOMOLOGY MEDICINES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is HOMOLOGY MEDICINES INC worth?
HOMOLOGY MEDICINES INC (FIXX) has a market capitalization of 54.23M USD. This makes FIXX a Micro Cap stock.
How many employees does HOMOLOGY MEDICINES INC have?
HOMOLOGY MEDICINES INC (FIXX) currently has 92 employees.
What are the support and resistance levels for HOMOLOGY MEDICINES INC (FIXX) stock?
HOMOLOGY MEDICINES INC (FIXX) has a support level at 0.92 and a resistance level at 0.94. Check the full technical report for a detailed analysis of FIXX support and resistance levels.
Is HOMOLOGY MEDICINES INC (FIXX) expected to grow?
The Revenue of HOMOLOGY MEDICINES INC (FIXX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the FIXX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy HOMOLOGY MEDICINES INC (FIXX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of FIXX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of FIXX, evaluating the profitability, health, valuation and growth aspects
- HOMOLOGY MEDICINES INC (FIXX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HOMOLOGY MEDICINES INC (FIXX) Sales and EPS estimates to see what analysts future expectations are.
- HOMOLOGY MEDICINES INC (FIXX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HOMOLOGY MEDICINES INC (FIXX) Insider and Institutional Ownership to learn about the owners and their transactions.
- HOMOLOGY MEDICINES INC (FIXX) Stock Chart to make your own analysis
- HOMOLOGY MEDICINES INC (FIXX) Latest news and press-releases to stay up to date.
Does HOMOLOGY MEDICINES INC (FIXX) stock pay dividends?
FIXX does not pay a dividend.
When does HOMOLOGY MEDICINES INC (FIXX) report earnings?
HOMOLOGY MEDICINES INC (FIXX) will report earnings on 2024-05-09, after the market close.
What is the Price/Earnings (PE) ratio of HOMOLOGY MEDICINES INC (FIXX)?
HOMOLOGY MEDICINES INC (FIXX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.96).
FIXX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to FIXX. When comparing the yearly performance of all stocks, FIXX is one of the better performing stocks in the market, outperforming 81.09% of all stocks.
FIXX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FIXX. FIXX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
FIXX Financial Highlights
Over the last trailing twelve months FIXX reported a non-GAAP Earnings per Share(EPS) of -1.96. The EPS decreased by -3.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -133.57% | ||
| ROE | -154.74% | ||
| Debt/Equity | 0 |
FIXX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to FIXX. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 64.09% and a revenue growth -100% for FIXX